Gene Expression in Patients With Advanced or Metastatic Colorectal Cancer Receiving Bevacizumab
Completed
- Conditions
- Colorectal Cancer
- Registration Number
- NCT00897754
- Lead Sponsor
- ECOG-ACRIN Cancer Research Group
- Brief Summary
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors understand how patients respond to treatment.
PURPOSE: This laboratory study is looking at gene expression in patients with advanced or metastatic colorectal cancer receiving bevacizumab.
- Detailed Description
OBJECTIVES:
* Determine whether the balance of splice form expression alters susceptibility of tumors in vivo to respond to anti-VEGF therapy.
OUTLINE: Tumor tissue samples collected on clinical trial E-3200 are analyzed for laboratory endpoints.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Mean scores for VEGFb and pan-VEGF gene expression by IHC 1 month Gene expression as measured by tissue microarrays 1 month Splice form expression as measured by reverse transcriptase-PCR 1 month VEGF165b protein expression as measured by ELISA 1 month
- Secondary Outcome Measures
Name Time Method